We anticipate that glioma tissues with relatively more MBD3 would respond better to therapeutic vaccination and immune-checkpoint-blockade agents (e.g., PD-1/PD-1L inhibitors and CTLA-4 blockade). The gene discussed is CTLA4; the disease is central nervous system cancer.